Watch-List: NewLink Genetics (NLNK), NPS Pharmaceuticals (NPSP), NPS Pharmaceuticals (NPSP)

Human testing of NewLink Genetics Corp (NASDAQ:NLNK)’s promising Ebola vaccine has been launched. That goes along away to explain the positive momentum in the stock. The company said it was testing the vaccine, known as VSV-EBOV, first on a small group of people. The ongoing test seeks to evaluate whether the drug is safe for use in humans and the size of the dose required in providing immunity in humans.

NewLink Genetics Corp (NASDAQ:NLNK)’s Ebola vaccine is already successful in monkeys, but it had not be tried in humans. The outbreak of Ebola appears to have accelerated the development of the vaccine, especially for human use now that Ebola is causing havoc all around the world. The outbreak that started in some pockets of the African continent has now spread to the U.S., where two nurses at a hospital in Dallas have been confirmed to have the virus.

Shares of NewLink Genetics Corp (NASDAQ:NLNK) have gained more than 11% so far this year as investors step up their positive bet on the stock owing to the Ebola prospects.

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) now carries Wall Street consensus rating of a “buy” and average objective price of $37.45. That reflects the views of 13 rating firms that are covering the stock currently.

A number of firms including FBR Capital have recently weighed in on the stock of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP). Analysts at FBR Capital, for instance, have an “outperform” rating on the stock and a target price of $36, up from $34 previously.

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) posted a profit of $0.02 per share on revenue of $53.06 million in the latest quarter. However, analysts on the average now expect it to report a profit of $0.01 per share on revenue of $59.54 million in the upcoming report.

Cavium Inc (NASDAQ:CAVM) will report its 3Q2014 financial results on October 29. The release of the results will be followed by a conference call about an hour later to discuss the performance and review the business condition. Analysts on the average expect the company to post a profit of $0.39 per share on revenue of $97.10 million in the upcoming report.

Cavium Inc (NASDAQ:CAVM) edged out estimated in the last quarter whereby it posted EPS of $0.35 against $0.33 and revenue of $90.70 million against $90.04 million. Revenue also soared more than 22% from the same quarter in the prior year.

About the Author

Terrel is US Markets Daily's business news reporter. She joined US Markets Daily after five years as a print reporter.

Leave A Response